VSTM · Verastem, Inc. · Stock research

Current Thesis

The July gap between an accelerating KRAS science story and a tape that would not confirm it closed on 2026-08-06, and the two weeks since have been quiet. Q2 put AVMAPKI FAKZYNJA CO-PACK net product revenue at $25.1M against $23.093M consensus, total revenue at $40.1M versus $2.1M in Q2 2025, and a GAAP loss of $0.35 per share against a consensus $(0.43). The undated VS-7375 readout became "October 2026," and a royalty facility with Oberland Capital replaced the equity-raise question with a funding date. Price went $5.53 (2026-07-12 close) to $6.74 (2026-08-07) to $6.89 (2026-08-21) — the second leg is roughly +2% over two weeks, with RSI(14) at 67.9 and price still 36.0% below the 52-week high of $10.77. What an investor is buying is a commercial low-grade serous ovarian cancer franchise that management expects to be self-sustaining by end-2026, funding a land-grab in oral KRAS G12D — with the repricing event, preliminary Phase 2 response rates across pancreatic, lung and colorectal cancer at roughly 20 patients per tumor type, still roughly two months out. Inside 30 days the only dated item is a financing close.

Bullish and bearish views on Verastem, Inc.

The model's bull view on Verastem, Inc. (VSTM), in brief: Q2 2026 (2026-08-06): total revenue $40.1M versus $2.1M in Q2 2025; co-pack net product revenue $25.1M against $23.093M consensus; GAAP net loss $34.7M, $0.35 per share, versus a $(0.43) consensus loss estimate. The bear view: The direction of sell-side revisions is down while the tape is up. Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-06): total revenue $40.1M versus $2.1M in Q2 2025; co-pack net product revenue $25.1M against $23.093M consensus; GAAP net loss $34.7M, $0.35 per share, versus a $(0.43) consensus loss estimate.
• Financing is non-dilutive and dated. Cash, equivalents and investments were $136.4M at 2026-06-30; pro forma $201.4M including the Oberland facility and a $15M COPIKTRA milestone from Secura Bio. $50M funds at closing on 2026-08-28; up to $25M more is available at the company's option if calendar-quarterly worldwide co-pack net sales reach $40M before 2027-05-15. Runway is guided into H2 2027.
• The June dataset gave the October update a starting point: at a 2026-06-12 cutoff, VS-7375 was dosed at 600 mg once daily in 57 patients and 900 mg once daily in 25 patients with mostly low-grade GI toxicity, and 93% of 14 metastatic pancreatic patients at 900 mg showed a greater-than-50% CA19-9 reduction (2026-06-23 release). RAMP 205 showed 86% six-month survival in first-line metastatic pancreatic cancer (2026-06-17).
• Three registration-directed Phase 2 trials dosed inside six weeks: TARGET-D 201 (2L metastatic PDAC) 2026-06-16, TARGET-D 202 (2L/3L NSCLC) 2026-07-22, TARGET-D 203 (metastatic CRC) 2026-07-28. FDA granted Fast Track to VS-7375 in KRAS G12D-mutated advanced NSCLC on 2026-06-03. Phase 2 enrollment completion is targeted by end-2026, an FDA meeting on Phase 3 design before year-end, Phase 3 enrollment initiation in H1 2027.
• Every covering bank named in the last two months holds a Buy or Outperform: HC Wainwright $18 and BTIG $18 (both 2026-06-24), RBC $14 (2026-07-07), Mizuho $13 (2026-08-11), Guggenheim $12 (2026-08-07) — a $12–$18 band against the 2026-08-21 close of $6.89.

Bear Case

• The direction of sell-side revisions is down while the tape is up. RBC cut to $14 on 2026-07-07, Guggenheim to $12 on 2026-08-07, Mizuho to $13 on 2026-08-11. That is three cuts in six weeks with no rating changes — the prior note flagged "a third target cut" as the observable that would confirm this risk, and it has now printed.
• October is preliminary Phase 2 data at roughly 20 patients per tumor type. Cohorts that size support a directional read on activity, and cannot settle superiority against Revolution Medicines' RMC-9805 or the Astellas and BMS programs aimed at the same mutation.
• The contingent $25M Oberland tranche requires quarterly co-pack net sales of $40M before 2027-05-15, against $25.1M booked in Q2 2026. That is a large step-up on a rare-indication launch and it carries a hard expiry.
• The royalty facility is non-dilutive to shareholders but encumbers the one revenue-generating asset. Runway guided into H2 2027 runs against Phase 3 enrollment starting H1 2027, so the spend commitment ramps before the funded window ends.
• AVMAPKI FAKZYNJA holds accelerated approval (FDA, 2025-05-08); the RAMP 301 confirmatory topline is not guided until mid-2027, so conditional-approval risk stays live for roughly a year.
• Price is 36.0% below the $10.77 52-week high despite gaining 62.5% over three months. The Q2 beat did not carry price back toward the June levels.

Setup & Price Structure

• Reference close 2026-08-21: $6.89. Three-month price change +62.5%. RSI(14) 67.9. Distance from the 52-week high of $10.77: -36.0%.
• The post-print leg has flattened: $6.74 on 2026-08-07 to $6.89 on 2026-08-21, with RSI essentially unchanged (68.1 to 67.9). Momentum has been held, not extended.
• The structure being defended is the post-Q2 shelf built off the 2026-07-12 close of $5.53. A weekly close below $5.50 would hand back the entire earnings-and-financing advance.
• The narrative is maturing. The repricing headlines are dated 2026-06-17 (RAMP 205), 2026-06-23 (TARGET-D 101), 2026-08-06 (Q2 plus Oberland). Since then the only new item is 2026-08-11, a price-target cut. Attention exists and the name is known; the incremental bid has thinned while the next catalyst sits outside the window.
• Crowding and positioning observables, stated as observables: RSI(14) at 67.9 with price still a third below the 52-week high; five price targets clustered $12–$18 while three of them were reduced inside six weeks; the capital raise took a royalty form rather than equity, and no offering has been announced since the Q2 print as of 2026-08-21; the nearest dated event is a financing close rather than a data release.

Catalyst Calendar (next 30 days)

• 2026-08-28 — Closing of the Oberland Capital royalty financing, $50M funded. The one dated item inside the window.
• ~2026-09-30 (est.) — No company-confirmed event between the Oberland close and the October data update; the company has not guided a September disclosure.
• ~2026-10-31 (est.) — VS-7375 TARGET-D update: response rates across PDAC, NSCLC and CRC, roughly 20 patients per tumor type. Outside 30 days.
• ~2026-11-05 (est.) — Q3 2026 results, on the 2026-05-07 / 2026-08-06 cadence; date not confirmed by the company.

What Would Change Our Mind

The structure at risk is the shelf laid down between the 2026-07-12 close of $5.53 and the 2026-08-07 close of $6.74 — the whole advance is the market paying for a revenue beat plus a non-dilutive financing plus a dated readout. A weekly close below $5.50 removes all three from the price and puts the name back where it sat when the catalyst had no date. Three other things would flip the read independent of price: the 2026-08-28 Oberland closing failing to fund $50M, which reopens the equity-issuance question the Q2 print was supposed to have closed; October ending with no VS-7375 response-rate disclosure, which returns the binary to the undated state that made this untradeable in July; and a Q3 print (~2026-11-05 est.) with co-pack net product revenue at or below the $25.1M booked in Q2, which would put the $40M quarterly bar for the contingent tranche out of reach and undercut the self-sustaining-by-end-2026 claim. A fourth rating action taking a target below $10 would mark the sell-side band converging toward the tape rather than the reverse.

Correlation Notes

• Direct read-across to the oral KRAS G12D complex: Revolution Medicines (RMC-9805), Astellas and BMS. A competitor PDAC or NSCLC dataset landing in the same October window is the single most likely source of an exogenous move.
• Partner GenFleet Therapeutics runs a Phase 1/2 monotherapy study of the same molecule (GFH375) in China; its data releases move VSTM off the US trial cadence.
• Unprofitable, single-product commercial-stage biotech trades with small-cap biotech beta (XBI) and with rate expectations; the 62.5% three-month advance was earned on company events, but the drawdown correlation to the sector is not company-specific.
• The revenue line is a single-indication launch (LGSOC). Payer, prescriber-uptake and gross-to-net commentary at the Q3 print drives the co-pack number more than anything in the KRAS pipeline does.